Core Viewpoint - Rosen Law Firm is reminding investors who purchased Flywire Corporation securities during the specified Class Period of the upcoming lead plaintiff deadline on September 23, 2025, for a class action lawsuit [1]. Group 1: Class Action Details - Investors who bought Flywire securities between February 28, 2024, and February 25, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and those wishing to serve as lead plaintiff must act by September 23, 2025 [3]. - The lawsuit alleges that Flywire's management made false and misleading statements regarding the company's revenue growth and the impact of permit and visa-related restrictions on its business [5]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, highlighting its own success in recovering hundreds of millions of dollars for investors [4]. - The firm achieved the largest securities class action settlement against a Chinese company at the time and has been consistently ranked among the top firms for securities class action settlements since 2013 [4].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Lockheed Martin securities between January 23, 2024, and July 21, 2025, of the September 26, 2025, deadline to become lead plaintiffs in a class action lawsuit [1]. Group 1: Class Action Details - Investors who purchased Lockheed Martin securities during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by September 26, 2025 [3]. - The Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [4]. Group 2: Allegations Against Lockheed Martin - The lawsuit alleges that Lockheed Martin made false and misleading statements and failed to disclose critical information regarding its internal controls and risk management practices [5]. - Specific claims include Lockheed Martin's lack of effective internal controls over risk-adjusted contracts, inaccurate program reviews, and overstated capabilities in delivering contract commitments [5]. - As a result of these alleged misrepresentations, the lawsuit claims that investors suffered damages when the true details became public [5].

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Quantum Corporation To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Quantum Corporation between November 15, 2024 and August 18, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, Sept. 11, 2025 ...

Core Viewpoint - Rosen Law Firm is reminding investors who purchased securities of RxSight, Inc. during the specified class period of the upcoming lead plaintiff deadline for a class action lawsuit [1][2]. Group 1: Class Action Details - The class period for the lawsuit is from November 7, 2024, to July 8, 2025, and investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by September 22, 2025 [2]. Group 2: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company at the time and being ranked No. 1 for the number of settlements in 2017 [3]. - The firm has recovered hundreds of millions of dollars for investors, securing over $438 million in 2019 alone [3]. Group 3: Case Allegations - The lawsuit alleges that RxSight made false and misleading statements regarding its sales and utilization, overstated demand for its products, and was unlikely to meet its financial guidance for fiscal year 2025 [4]. - The misleading statements led to investor damages when the true details about the company's performance were revealed [4].

Sep 11, 2025 3:45 PM Eastern Daylight Time NASDAQ: LNTH: Kessler Topaz Meltzer & Check, LLP Announces the Filing of a Securities Class Action Lawsuit Against Lantheus Holdings, Inc. Share RADNOR, Pa.--(BUSINESS WIRE)--The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed against Lantheus Holdings, Inc. ("Lantheus†) (NASDAQ: LNTH) on behalf of those who purchased or otherwise acquired Lantheus securities between February 26 ...

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against SelectQuote, Inc. due to allegations of violations of federal securities laws, particularly concerning misleading statements and illegal kickbacks related to Medicare beneficiaries [4][6][7]. Group 1: Allegations Against SelectQuote - The complaint alleges that SelectQuote directed Medicare beneficiaries to plans that compensated the company best, regardless of the quality of the plans [6]. - It is claimed that SelectQuote did not provide unbiased comparisons for Medicare Advantage insurance plans and received illegal kickbacks from insurers [6]. - The U.S. Department of Justice filed a complaint stating that SelectQuote received "tens of millions of dollars" in illegal kickbacks from 2016 to at least 2021 [7]. Group 2: Impact on Stock and Legal Proceedings - Following the DOJ's allegations, SelectQuote's stock price fell by $0.61, or 19.2%, closing at $2.56 per share on May 1, 2025, with unusually heavy trading volume [7]. - Investors who purchased SelectQuote securities between September 9, 2020, and May 1, 2025, are encouraged to discuss their legal rights and options [4][9]. - There is a deadline of October 10, 2025, for investors to seek the role of lead plaintiff in the federal securities class action against SelectQuote [4].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against PubMatic, Inc. due to allegations of violations of federal securities laws related to misleading statements and undisclosed information regarding ad spend reductions from a top demand-side platform (DSP) buyer [4][6]. Group 1: Legal Investigation - The law firm is encouraging investors who suffered losses in PubMatic between February 27, 2025, and August 11, 2025, to discuss their legal rights [1]. - There is a deadline of October 20, 2025, for investors to seek the role of lead plaintiff in a federal securities class action against PubMatic [4]. - The firm has a history of recovering hundreds of millions of dollars for investors since its founding in 1995 [5]. Group 2: Allegations Against PubMatic - The complaint alleges that PubMatic and its executives made false or misleading statements and failed to disclose significant changes in client behavior from a top DSP buyer [6]. - Specific allegations include a shift of clients to a new platform that evaluates inventory differently, leading to a reduction in ad spend and revenue for PubMatic [6]. - Following the release of its second quarter 2025 financial report, PubMatic's stock price fell by $2.23, or 21.1%, closing at $8.34 per share on August 12, 2025, due to the disclosed negative outlook [7]. Group 3: Class Action Participation - The lead plaintiff in a class action is defined as the investor with the largest financial interest who is adequate and typical of class members [8]. - Any member of the putative class can move the court to serve as lead plaintiff or choose to remain an absent class member without affecting their ability to share in any recovery [8]. - The firm is also seeking information from whistleblowers, former employees, and shareholders regarding PubMatic's conduct [9].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased LifeMD, Inc. securities between May 7, 2025, and August 5, 2025, about the upcoming lead plaintiff deadline for a securities class action lawsuit [1]. Group 1: Class Action Details - Investors who bought LifeMD securities during the specified Class Period may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by October 27, 2025 [3]. - The lawsuit alleges that defendants made materially false and misleading statements regarding LifeMD's competitive position and failed to account for rising customer acquisition costs, leading to investor damages when the truth was revealed [5]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, highlighting its own achievements, including the largest securities class action settlement against a Chinese company at the time [4]. - The firm has consistently ranked in the top 4 for securities class action settlements since 2013 and recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [4].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against LifeMD, Inc. due to allegations of violations of federal securities laws, particularly concerning misleading statements and financial guidance [3][4]. Group 1: Allegations Against LifeMD - The complaint alleges that LifeMD and its executives materially overstated the company's competitive position [3]. - It is claimed that the defendants were reckless in raising LifeMD's 2025 guidance without properly accounting for rising customer acquisition costs in the RexMD segment and related to obesity treatment drugs [3]. - As a result, statements made by the defendants regarding LifeMD's business and prospects were materially false and misleading [3]. Group 2: Financial Impact - On August 5, 2025, LifeMD reported its Q2 2025 financial results, revising its revenue guidance to a range of $250 to $255 million, down from a previous guidance of $268 to $275 million [4]. - Following this announcement, LifeMD's stock experienced a significant decline of 44.8% on August 6, 2025 [4]. Group 3: Legal Proceedings - Investors who purchased LifeMD securities between May 7, 2025, and August 5, 2025, are encouraged to contact Faruqi & Faruqi to discuss their legal rights and options [1]. - The deadline to seek the role of lead plaintiff in the federal securities class action against LifeMD is October 27, 2025 [1].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Flywire Corporation due to allegations of violations of federal securities laws, particularly concerning misleading statements about the company's revenue growth and the impact of permit-related restrictions on its business [3][4]. Group 1: Allegations and Financial Performance - The complaint against Flywire alleges that the company overstated the strength and sustainability of its revenue growth [3]. - It is claimed that the negative impact of permit- and visa-related restrictions on Flywire's business was understated [3]. - Flywire reported a net loss of $15.9 million for Q4 2024, missed consensus estimates, lowered its 2025 guidance, and announced a 10% workforce reduction [4]. Group 2: Stock Market Reaction - Following the release of its financial results and restructuring announcement, Flywire's stock price fell by $6.59 per share, or 37.4%, closing at $11.05 per share on February 26, 2025 [4]. Group 3: Legal Proceedings - Investors who purchased Flywire securities between February 28, 2024, and February 25, 2025, are encouraged to contact Faruqi & Faruqi to discuss their legal rights, with a deadline for seeking lead plaintiff status set for September 23, 2025 [1][5].